In triple‐negative breast cancer, loss of BRCA1 activates nuclear CatL‐mediated p53‐binding protein 1 degradation, which acts as a replacement of BRCA1 that bypasses growth arrest and increases the survival of tumor cells. Here, BRCA1 is linked to neoplasm.